TD Asset Management
CERE

TD Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

TD Asset Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-372,146
Closed -$8.12M – 1463
2023
Q3 		$8.12M Buy
372,146
+168,697
+83% +$4.22M 0.01% 624
2023
Q2 		$6.47M Buy
203,449
+22,226
+12% +$682K 0.01% 685
2023
Q1 		$4.42M Sell
181,223
-4,321
-2% -$127K 0.01% 776
2022
Q4 		$5.85M Hold
185,544
– – 0.01% 704
2022
Q3 		$5.17M Buy
185,544
+2,536
+1% +$75.5K 0.01% 744
2022
Q2 		$4.84M Sell
183,008
-12,800
-7% -$363K 0.01% 781
2022
Q1 		$6.86M Sell
195,808
-20,300
-9% -$593K 0.01% 751
2021
Q4 		$7.01M Buy
216,108
+41,632
+24% +$1.47M 0.01% 773
2021
Q3 		$5.15M Buy
174,476
+19,886
+13% +$558K 0.01% 808
2021
Q2 		$3.81M Buy
154,590
+39,875
+35% +$571K ﹤0.01% 909
2021
Q1 		$1.57M Buy
114,715
+77,557
+209% +$1.13M ﹤0.01% 1163
2020
Q4 		$616K Buy
+37,158
New +$483K ﹤0.01% 1291

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

TD Asset Management's CERE Position: Q4 2023 in Review

TD Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2023, closing a stake of 372,146 shares — an estimated $8.12M sold.

TD Asset Management first reported a position in CERE in Q4 2020 and held it in 12 quarters. The position peaked at $8.12M in Q3 2023. 195 funds tracked by Wall St. Rank hold CERE as of Q4 2023.

  • TD Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • TD Asset Management sold 372,146 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2023, an estimated $8.12M.
  • TD Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 12 quarters.
  • TD Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $8.12M in Q3 2023.
  • 195 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2023.

Based on TD Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.